can the trm psoriasis skewed cels be genetically modified to remove the error?

Genetic modification of psoriasis-skewed T cells to correct underlying abnormalities is currently not a standard clinical practice and remains an area of experimental and translational research rather than an established therapeutic option.

Psoriasis involves complex immune dysregulation where pathogenic CD4+ tissue-resident memory T cells (TRM), characterized by markers such as IL-17RA+, IL-22+, PD1+, CXCR6+, CD103+, and CD69+, persist in psoriatic skin plaques and sustain chronic inflammation through memory-driven inflammatory cytokine production NICE CKS Lei et al. 2025. These TRM cells are retained in skin via integrins (CD103+) and activation markers (CD69+), enabling longevity and rapid reactivation NICE CKS Lei et al. 2025. Their pathological activity is integral to disease chronicity and relapse NICE CKS Lei et al. 2025.

Current standard treatments, including topical therapies and systemic biologics, modulate cytokine signaling pathways (e.g., IL-17, IL-23, TNF-α) to reduce inflammatory responses but do not genetically alter T cells to reverse intrinsic abnormalities or correct their pathogenic memory state NICE CKS,NICE CG153. While biologic agents effectively inhibit cytokine effectors and signaling, they do not modify the genetic or epigenetic programming of TRM cells NICE CG153.

Recent proteomic and molecular studies highlight critical molecular pathways involved in psoriasis inflammation, such as the NF-κB pathway, and implicate molecules like Pggt1b in macrophage activation and cytokine secretion that propagate psoriatic inflammation Yu et al. 2025. However, these insights have not yet translated into feasible genetic modification of T cells in clinical psoriasis management.

Advances in extracellular vesicle (EV) research demonstrate roles of EV-mediated communication in propagating TNF-α, IL-17A, IL-22, and other cytokines among keratinocytes, macrophages, and T cells, reinforcing chronic inflammation and immune cell polarization in psoriasis Lei et al. 2025. While EVs offer novel therapeutic targeting potentials and can be engineered to modulate immune responses, direct genetic reprogramming of psoriasis-associated TRM cells remains experimental at present.

The complexities of psoriasis pathophysiology, involving both genetic susceptibility and environmental triggers mediated through memory T cell populations, make precise gene editing or genetic reprogramming challenging. There is no clinical evidence or guideline recommending genetic modification of psoriatic T cells at this time NICE CKS,NICE CG153.

Finally, emerging research exploring gene editing technologies, such as CRISPR-based approaches, targeting immune checkpoints or inflammatory signaling within immune subsets, is in early preclinical stages and may hold future promise for correcting pathogenic T cell phenotypes in autoimmune diseases, including psoriasis. However, such techniques are not yet clinically available or guideline-endorsed for psoriasis treatment NICE CKS Yu et al. 2025Lei et al. 2025.

In summary, while psoriasis-associated skewed T cells represent a key pathogenic driver, genetic modification to remove their underlying abnormality is currently not an approved or practical therapeutic strategy, and management focuses on immunomodulation using topical and biologic therapies until gene therapies mature for clinical use.